New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs AOD-9604

Pancragen vs AOD-9604

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Fat Loss & Metabolic
AOD-9604
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
Half-Life
Short (minutes); sustained gene-regulatory effects
30-45 minutes injectable; longer with nasal spray formulation
Admin Route
SubQ, Oral
SubQ, Intranasal, Oral
Research
Typical Dose
10 mg per day
300-600 mcg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Selective fat loss without anabolic side effects
  • No effect on blood glucose or insulin resistance
  • Improved bioavailability over Fragment 176-191
  • GRAS (Generally Recognized As Safe) status in Australia
  • Potential cartilage repair and anti-inflammatory properties
  • Does not suppress natural GH production
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Localized injection site reactions
  • Headache (rare)
  • Hypoglycemia risk in combination with insulin (very rare)
Stacks With